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Researcher
honored for
‘Outstanding
Early Career’
Dr. Matthew Banks, an assistant professor of
pharmacology, received the award at VCU’s fall
convocation. He conducts research on how to
treat drug addiction.
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T

he United States is facing a heroin and opioid
epidemic, with fatal drug overdoses steadily
rising over the past 15 years. Scientists and
doctors are working hard researching addiction
and developing new ways to treat the growing
issue.
One such researcher is Dr. Matthew L. Banks,
an assistant professor in VCU’s Department
of Pharmacology and Toxicology. For his
work in this area, Banks recently received the
university’s Outstanding Early Career Faculty
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Award.
His research centers on two themes –
developing behavioral and pharmacological
strategies to treat drug addiction, and making
existing medications more effective with fewer
side effects. Much of his work at the Medical
College of Virginia involves rhesus monkeys.
“The research we do is intended to improve
human health and also has applications to
improving veterinary medicine,” said Banks, who
was honored at VCU’s faculty convocation at the
start of the fall semester.
Banks received his doctorate in pharmacy from
Ohio Northern University and his Ph.D. from
Wake Forest University. He was introduced
to drug abuse research in pharmacy school,
though his interest in the field stemmed from
his experience as a runner who would often
experience the “runner’s high”.
Dr. Matthew L. Banks

Monkeys are a good
model for understanding
why humans ‘go along
this path of misallocating
their behavior to abused
drugs,’ Banks says.

Currently, Banks is researching whether the
use of an NMDA receptor antagonist called
memantine would create an opioid sparing
effect. The goal is to increase the therapeutic
effect of an opioid, requiring a user to take less
of the drug for pain management. An NMDA
antagonist inhibits the action of the brain’s
N-Methyl-D-aspartate receptor.
The use of animals in research can be
controversial. The MCV campus houses a lab
of rhesus monkeys, which are involved in much
of Banks’ research. The Institutional Animal
Care and Use Committee at VCU, as well as
the federal agency providing a research grant,
must review any proposals for use of laboratory
animals to ensure the use is justified and
the health and welfare of the animals will be
protected. When not being studied, the monkeys
live in a vivarium on campus.
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Banks’ research on the
drug phendimetrazine
suggests that it may be
a viable treatment for
cocaine addiction.
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Research on animals can yield tremendous
benefits. While primates make up only a half
percent of all laboratory animals used, they have
been crucial in many medical advances such as
developing the polio vaccine, understanding the
AIDS virus and searching for a vaccine for the
Zika virus.
Humans share 90 percent of their genes with
monkeys. Monkeys are a good model for
understanding why humans “go along this path
of misallocating their behavior to abused drugs,”
Banks said.
Such research can help clinicians treat people
with addictions and “get them to reallocate their
behavior back to socially adaptive non-drug
reinforcers,” he said.
While multiple pharmacotherapies exist for
treating opiate addiction (such as methadone),
the U.S. Food and Drug Administration has
not approved treatments for cocaine and
methamphetamine addiction.
Banks’ research on the drug phendimetrazine
suggests that it may be a viable treatment for
cocaine addiction. It “decreases cocaine vs.
food choice under several different experimental
conditions,” which means monkeys are more
likely to choose food over cocaine after being
administered the drug.
The compound acts as a dopamine transporter
inhibitor like cocaine. Because it is a “prodrug,”
the body metabolizes it into a pharmacologically
active compound called phenmetrazine that
acts as a dopamine transporter substrate (or
releaser). This combination may represent an
“innovative treatment strategy for cocaine use
disorders,” Banks said.
He has discovered that although cocaine
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and methamphetamine share similar
properties, the two drugs will require different
pharmacotherapies to treat their abuse. To
Banks, these discoveries are exciting as they
represent exactly what “preclinical researchers
hope to do – that is, impact human health in a
positive manner.” •

